Pharmatek Revenue and Competitors
Estimated Revenue & Valuation
- Pharmatek's estimated annual revenue is currently $16.3M per year.
- Pharmatek's estimated revenue per employee is $201,000
Employee Data
- Pharmatek has 81 Employees.
- Pharmatek grew their employee count by 9% last year.
Pharmatek's People
Name | Title | Email/Phone |
---|
Pharmatek Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is Pharmatek?
Pharmatek Laboratories, Inc. is a premier pharmaceutical chemistry development and manufacturing organization supporting the pharmaceutical and biotechnology industries. Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection, analytical methods development, preformulation testing, formulation development, cGMP manufacturing, clinical packaging, labeling & worldwide distribution, stability storage and testing, as well as development and manufacturing support for highly-potent & cytotoxic (HP/C) compounds. Pharmatek’s unique client-centric approach to drug development brings quality people, quality science and quality systems to every project. Learn more online at www.Pharmatek.com. For more information on job openings, go to http://www.pharmatek.com/careers.html.
keywords:N/AN/A
Total Funding
81
Number of Employees
$16.3M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $19.4M | 81 | 8% | N/A |
#2 | $20.6M | 81 | 13% | N/A |
#3 | $17M | 81 | -41% | N/A |
#4 | $21.9M | 81 | 3% | N/A |
#5 | $7.5M | 81 | 4% | N/A |